DS
BHVN

David Shaw’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

David Shaw’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-101,674
Closed -$15.4M – 5608
2022
Q3 		$15.4M Sell
101,674
-127,073
-56% -$18.8M 0.02% 1030
2022
Q2 		$33.3M Buy
228,747
+221,116
+2,898% +$28.2M 0.04% 584
2022
Q1 		$905K Sell
7,631
-43,376
-85% -$5.41M ﹤0.01% 3998
2021
Q4 		$7.03M Sell
51,007
-69,703
-58% -$8.86M 0.01% 2023
2021
Q3 		$16.8M Buy
120,710
+72,656
+151% +$9.07M 0.02% 1135
2021
Q2 		$4.67M Sell
48,054
-90,281
-65% -$7.33M ﹤0.01% 2115
2021
Q1 		$9.46M Sell
138,335
-25,174
-15% -$2.04M 0.01% 1396
2020
Q4 		$14M Sell
163,509
-16,388
-9% -$1.39M 0.01% 1169
2020
Q3 		$11.7M Buy
179,897
+55,957
+45% +$3.67M 0.01% 1143
2020
Q2 		$9.06M Sell
123,940
-14,957
-11% -$796K 0.01% 1244
2020
Q1 		$4.73M Buy
138,897
+2,632
+2% +$120K 0.01% 1512
2019
Q4 		$7.42M Sell
136,265
-58,989
-30% -$2.92M 0.01% 1421
2019
Q3 		$8.15M Sell
195,254
-41,662
-18% -$1.76M 0.01% 1307
2019
Q2 		$10.4M Buy
236,916
+197,879
+507% +$11.2M 0.01% 1117
2019
Q1 		$2.01M Buy
+39,037
New +$1.69M ﹤0.01% 2155

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

David Shaw's BHVN Position: Q4 2022 in Review

David Shaw sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 101,674 shares — an estimated $15.4M sold.

David Shaw first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $33.3M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • David Shaw reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • David Shaw sold 101,674 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $15.4M.
  • David Shaw first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • David Shaw's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33.3M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.